본문 바로가기

Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q3Scopus Q2
저널
JOURNAL OF KOREAN MEDICAL SCIENCE29(1) · pp.90 · 2014
피인용
Web of Science 50KCI 1
JCR IF
JCR 2013 1.253
ISSN
1011-8934

저자

  1. 이미영연세대학교
  2. 최동섭교신저자고려대학교
  3. 이문규성균관대학교
  4. 이형우영남대학교
  5. 박태선전북대학교
  6. 김두만한림대학교
  7. 김인주부산대학교
  8. 장학철서울대학교
  9. 박용수한양대학교
  10. 권혁상가톨릭대학교
  11. 이승훈가톨릭대학교
  12. 정춘희연세대학교
  13. 김덕규동아대학교
  14. 신희강Bayer Korea Ltd.

초록

We studied the efficacy and safety of acarbose in comparison with voglibose in type 2 diabetes patients whose blood glucose levels were inadequately controlled with basal insulin alone or in combination with metformin (or a sulfonylurea). This study was a 24-week prospective, open-label, randomized, active-controlled multi-center study. Participants were randomized to receive either acarbose (n= 59, 300 mg/day) or voglibose (n = 62, 0.9 mg/day). The mean HbA(1c) at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose (from 8.43% +/- 0.71% to 7.71% +/- 0.93%) and voglibose groups (from 8.38% +/- 0.73% to 7.68% +/- 0.94%). The mean fasting plasma glucose level and self-monitoring of blood glucose data from 1 hr before and after each meal were significantly decreased at week 24 in comparison to baseline in both groups. The levels 1 hr after dinner at week 24 were significantly decreased in the acarbose group (from 233.54 +/- 69.38 to 176.80 +/- 46.63 mg/dL) compared with the voglibose group (from 224.18 +/- 70.07 to 193.01 +/- 55.39 mg/dL). In conclusion, both acarbose and voglibose are efficacious and safe in patients with type 2 diabetes who are inadequately controlled with basal insulin.

키워드

Diabetes Mellitus, Type 2AcarboseVogliboseIMPAIRED GLUCOSE-TOLERANCEGLYCEMIC CONTROLPOSTPRANDIAL HYPERGLYCEMIACARDIOVASCULAR BENEFITS24-WEEK MONOTHERAPYCONTROLLED-TRIALNIDDM PATIENTSWEIGHT-GAINGLARGINEEFFICACY

식별자

WoS UID
000330508600014
KCI
ART001844603